Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort
Conclusions: These results confirm the activity of targeted therapy in patients with BRAF-mutant lung adenocarcinoma. Further trials are warranted to study combination therapies and drug resistance mechanisms.
Source: Journal of Thoracic Oncology - Category: Cancer & Oncology Tags: Original Articles Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Lung Cancer | Sarcomas | Smokers | Study